Uridine

Uridine is one of the four building blocks your body uses to make RNA (the molecule that carries instructions from your DNA out to the rest of the cell). It's also a key ingredient your brain uses to build and repair synapses, the connection points between neurons where thinking, learning, and memory actually happen. Specifically, your brain converts uridine into phosphatidylcholine, the main fatty material that synaptic membranes are made of. Think of phosphatidylcholine as the construction material, and uridine as one of the three raw ingredients needed to manufacture it.

People take it as a nootropic (a supplement aimed at cognitive performance) for memory, focus, and mood. The most common form is uridine monophosphate, or UMP, which is uridine with a phosphate group attached, basically a more usable version that your body can plug straight into the synthesis pathway. It's typically stacked with choline and an omega-3 fatty acid (DHA), since those are the other two raw ingredients your brain needs alongside uridine to actually build new synaptic material. Solo uridine does something, but the three together do considerably more.

Your liver makes uridine on its own, and plasma levels stay in a tight range regardless of diet. The foods often cited as uridine sources (tomatoes, broccoli, organ meats, oats) mostly contain it bound up in RNA, which gets degraded by your gut and liver before reaching your bloodstream. Only beer, sugar cane extract, and breast milk reliably raise plasma uridine. So is about pushing levels above baseline to drive faster synaptic membrane synthesis when the brain actually needs it.

Deep-dive

Uridine is a pyrimidine nucleoside, uracil bonded to a ribose sugar. Your liver and kidneys make it endogenously, and plasma levels sit in a tight range of roughly 3-8 μM across species. It enters cells via nucleoside transporters and gets phosphorylated to UMP, then UDP, then UTP. UTP is the substrate for RNA synthesis and, more importantly for nootropic purposes, it gets converted to CTP and then CDP-choline, the immediate precursor to phosphatidylcholine. Phosphatidylcholine is the dominant phospholipid in neuronal membranes and synaptic vesicles, so uridine availability is rate-limiting for membrane synthesis when demand is high.

The Kennedy pathway and why the stack matters. Phosphatidylcholine synthesis runs through the Kennedy pathway, which needs three substrates simultaneously: uridine (becoming CDP), choline (the head group), and DHA or another fatty acid (the tail). Richard Wurtman's lab at MIT spent decades showing that giving rodents all three together produces dramatic increases in dendritic spine density and synaptic protein levels, while giving any one alone produces much smaller effects. This is the basis for Souvenaid, a medical food containing UMP, choline, and DHA plus B vitamins, that's been tested in multiple Alzheimer's trials.

What the human evidence actually shows. A 2010 trial in 17 healthy men gave 2g of uridine daily for 7 days and found measurable increases in brain phospholipid precursors on MRS imaging. So the substrate effect is real and shows up fast. Whether that translates into noticeable cognitive gains is where the evidence gets thinner. The LipiDiDiet trial ran 311 people with prodromal Alzheimer's on the full UMP+choline+DHA stack for two years and found slowed brain atrophy and improvements on some cognitive measures. The earlier Souvenaid trials in mild Alzheimer's showed memory benefit, but the S-Connect trial in mild-to-moderate Alzheimer's found no effect, suggesting the window is early disease, not advanced. In healthy young adults, controlled cognitive trials of uridine alone are basically non-existent. The nootropic case in healthy people rests on mechanism plus extrapolation, not direct evidence.

Mood and bipolar depression. This is where uridine has the strongest non-Alzheimer's signal. An open-label trial in 7 depressed adolescents with bipolar disorder gave 500mg twice daily for 6 weeks and saw a 54% drop in depression rating scores, with no induced mania. A separate trial used triacetyluridine (a uridine prodrug) up to 18g/day for 6 weeks in 11 bipolar depressed adults and found reductions in depression scores alongside increased brain pH on MRS, suggesting improved mitochondrial bioenergetics. The hypothesis is that uridine corrects the mitochondrial dysfunction that's been documented in bipolar brains. Phase 2 trials by Repligen of an oral uridine prodrug (RG2417) for bipolar 1 depression went forward on the back of this signal but didn't end up producing a marketed product. Worth knowing if you have a family history or treatment-resistant depressive symptoms, but this isn't approved therapy.

Dopamine and acetylcholine. Uridine activates P2Y2 receptors on neurons, which appears to drive neurite outgrowth and synaptogenesis. It also seems to modulate dopaminergic and cholinergic signalling indirectly through CDP-choline production, choline being the precursor for acetylcholine. The dopamine receptor density claim that gets repeated in nootropic forums comes from rodent work and shouldn't be over-extrapolated. The cleaner mechanistic story is membrane synthesis enabling more synapses to function properly, with neurotransmitter effects downstream of that.

The metabolic catch. This is the limitation most nootropic content skips. Chronic high-dose uridine in mice induces fatty liver and pre-diabetic glucose intolerance over 16 weeks, mediated by O-GlcNAcylation of insulin signalling proteins like FOXO1. Plasma uridine is also a marker of insulin resistance in humans. The takeaway isn't that uridine causes diabetes at typical supplemental doses. It's that the relationship between uridine and metabolic health is biphasic: short-term acute use looks safe and possibly beneficial (it's used to rescue mitochondrial damage from anti-HIV drugs), while chronic high doses sustained over months may have downsides that haven't been characterised in humans. The authors of the mouse study explicitly argue that uridine should be used short-term and acute, not chronic. Worth taking seriously if you're planning to run it daily for years.

Women. Most uridine research has used mostly male subjects. The Souvenaid trials are an exception, the S-Connect trial was 52% women and the mechanism cuts identically across sexes, membrane synthesis is membrane synthesis. The bipolar depression open-label work included adolescent girls and showed comparable response. Hormonal cycling shouldn't meaningfully change uridine pharmacology. Skip during pregnancy and breastfeeding, not because of documented harm but because controlled data is essentially absent and uridine is naturally high in breast milk anyway.

Older adults. This is where the evidence is strongest. Plasma and brain uridine levels drop with age, choline uptake into the brain also declines, and DHA delivery is impaired in APOE4 carriers. The pathologic shortage of all three precursors in early Alzheimer's is the rationale Wurtman built the whole research programme on. If you're over 60 and looking at cognitive maintenance, the stacked approach (UMP + choline + omega-3) has the strongest mechanistic and clinical case of any consumer nootropic, with the caveat that effect sizes in trials have been modest and the most rigorous trial in advanced disease was negative.

Dosage:

Standard dose: 250-500 mg of uridine monophosphate (UMP) daily, taken sublingually or with food. Most clinical trials in humans have used 500-1000 mg/day. The Souvenaid formula delivers 625 mg of UMP

Always stack with choline and an omega-3. Uridine alone underperforms the combination dramatically. Pair with 250-500 mg of CDP-choline or alpha-GPC and 1-2g of DHA-rich fish oil. This is the protocol with actual human clinical evidence behind it

Sublingual vs oral: UMP is moderately absorbed orally but sublingual administration bypasses first-pass metabolism and gets more into circulation. If you can find sublingual tablets, use them. Otherwise oral is fine

Timing: Take with breakfast or lunch. Some people report mild stimulation that can interfere with sleep if taken late

Cycle considerations: Given the metabolic concerns from chronic high-dose rodent data, running 5 days on, 2 days off, or 8 weeks on with a 2 week break, is a sensible default for daily users. There's no strong human evidence that cycling is necessary, but it's a reasonable hedge against the long-term unknowns

Older adults targeting cognitive maintenance: stick to the full stack at the higher end (500-625 mg UMP, 400 mg choline, 1.2g DHA) daily. Effect builds over months, not days

Younger adults using as a nootropic: 250-500 mg UMP plus choline and DHA is enough. Don't expect a noticeable acute effect. If you don't feel anything in 4-6 weeks, you probably aren't going to

Forms: Triacetyluridine (TAU) is a fat-soluble prodrug with better bioavailability and brain penetration but is more expensive and less widely available. Plain UMP is the standard. Uridine itself (the unphosphorylated form) is also sold but UMP is the form used in most clinical research

Here's what you can expect:

Nothing dramatic in the first week or two. Uridine isn't a stimulant and doesn't produce the kind of acute subjective hit that caffeine or tyrosine do. What people report on the stack (uridine + choline + DHA) over 4-12 weeks is somewhat clearer thinking, slightly better verbal recall, more emotional steadiness, and less of the brain fog that builds during demanding weeks. The signal is subtle. If you're looking for a noticeable cognitive lift in a single dose, this isn't the compound.

The honest framing is that uridine is a maintenance compound, not a performance one. It supports the underlying machinery your brain uses to keep synapses healthy. If that machinery is already running well (young, well-fed, well-rested), you may notice nothing. If it's compromised (older, early cognitive decline, depleted from prolonged stress, low-DHA diet), the stack has a real chance of producing a noticeable improvement over months. Expect to evaluate it on a 3-month timeline, not a one-week trial.

For mood, some people report a steadying effect within 2-4 weeks. The bipolar depression trials saw their effect at the 6-week mark.

Side effects & risks:

GI discomfort is the most common, mild nausea, loose stools, stomach upset. Usually resolves with food or by lowering the dose

Headache or mild fatigue in a minority of users, typically transient

Choline-related side effects when stacked, can include irritability, headache, or low mood in people who don't tolerate choline well. If this happens, lower the choline dose first, not the uridine

Bipolar mania risk: the bipolar trials specifically did not see treatment-emergent mania, but anyone with bipolar disorder should approach any compound that affects mood pathways with caution and ideally clinical supervision

Metabolic effects with chronic high doses: the mouse data showing fatty liver and insulin resistance at chronic high doses doesn't have a clean human equivalent, but it's worth knowing about, especially if you already have metabolic syndrome, fatty liver, or pre-diabetes. If you're in that category, keep doses on the lower end and cycle

Gout and uric acid: uridine sits in the same metabolic neighbourhood as purines and theoretically could shift uric acid handling. No documented cases of uridine triggering gout, but if you have a history, monitor

Pregnancy and breastfeeding: skip. No reason to think it's harmful, dietary uridine is high in breast milk, but controlled data is absent

5-fluorouracil (chemotherapy) interaction: uridine is used clinically as a rescue agent for 5-FU toxicity, which means it directly counteracts 5-FU's mechanism. Anyone on 5-FU or capecitabine for cancer should avoid uridine supplementation

Long-term human safety data is limited. Most controlled trials run weeks to months, with the LipiDiDiet trial at 24 months being the longest and showing no significant safety issues on the multinutrient stack. Beyond that, real-world long-term data thins out

🩸

Blood markers

Fasting glucose and HbA1c, baseline if you plan to use uridine chronically (daily for more than 8 weeks), and recheck at 3-6 months. The mouse data on insulin resistance is the most credible long-term concern, and these are the cheapest markers to catch a problem early.

ALT and AST (liver enzymes), baseline. Chronic uridine in mice produces fatty liver, and while this hasn't been documented in humans at supplemental doses, it's worth a reference point if you're running daily long-term.

Lipid panel (triglycerides, LDL, HDL), baseline if running long-term. Hepatic lipid accumulation in the mouse studies suggests this is a logical place to monitor.

Uric acid, only if you have a personal or family history of gout. Not standard for uridine supplementation otherwise.

For most people taking uridine in a UMP+choline+DHA stack at typical doses (250-625 mg UMP), no specific bloodwork is required. The people who actually need baseline labs are those planning chronic daily use above 1g, anyone with existing metabolic syndrome, fatty liver, or insulin resistance, and older adults who are already getting comprehensive bloodwork as part of their general workup.

Sold as a dietary supplement in most countries without prescription.